Menu
Not yet recruiting NCT06750991

CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p)

Phase II Interventional DLBCL

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: CDR-CHOP.
Who it may be relevant to
Registry conditions: DLBCL. Basic parameters: 18 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Prospective, Open-label Phase II Study of Chidamide, Decitabine Plus R-CHOP in Previously Untreated Diffuse Large B-cell Lymphoma With a Combination of TP53 Mutation and Del(17p)

Overview

This was an open, multicenter clinical study of newly treated DLBCL patients with TP53 mutations and del(17p) with IPI\>1. Participants who met the inclusion/exclusion criteria signed informed consent and received 1 course of R-CHOP, followed by the remaining 5 cycles courses of chidamide and decitabine combined with a standard-dose R-CHOP regimen.

Detailed description

This was an open, multicenter clinical study of newly treated DLBCL patients with TP53 mutations and del(17p) with IPI\>1. Participants who met the inclusion/exclusion criteria signed informed consent and received 1 course of R-CHOP, followed by the remaining 5 cycles courses of chidamide and decitabine combined with a standard-dose R-CHOP regimen. . Patients who achieve CR will continue with chidamide maintenance therapy (20mg, D1,4,8,11) or opt for autologous hematopoietic stem cell transplantation after completion of induction therapy, with maintenance therapy recommended for at least 1 year (unless intolerable side effects or disease progression occur). Concurrent follow-up assessment (patients will enter the follow-up period described in the time and event table) until the end of the specified follow-up period (total study duration is 3 years) or until the patient meets the exit criteria.

Interventions

  • Drug CDR-CHOP
    Rituximab 375 mg/m2 D1 Cyclophosphamide 750 mg/m2 D2 Doxorubicin 50 mg/m2 D2 Vincristine 1.4 mg/m2 D2 Prednisone 69 mg.m2 D2-6 Chidamide 20 mg/d D1,4,8,11 Decitabine 10 mg/m2 D-5 - -1

Primary outcome measures

  • PFS（Progression-free survival） [Time frame: 1-year]
Secondary outcome measures (3)
  • CRR（Complete response rate） [Time frame: End of treatment visit (6-8 weeks after last dose on Day 1 of Cycle 6 [Cycle length=21 days]]
  • OS（overall survival） [Time frame: 2-year]
  • ORR（overall response rate） [Time frame: End of treatment visit (6-8 weeks after last dose on Day 1 of Cycle 6 [Cycle length=21 days]]

Eligibility criteria

Inclusion criteria

  • 1\. Histologically confirmed diffuse large B-cell lymphoma with CD20 positive;
  • 2\. Pathologically confirmed a combination of TP53 mutation and del(17p);
  • 3\. Age ≥ 18 years old, ≦75 years old;
  • 4\. ECOG physical status score of 0, 1 or 2;
  • 5\. No previous history of malignant tumors; No other tumors occurred simultaneously;
  • 6\. Patients judged by the investigator to have a life expectancy of at least 6 months;
  • 7\. The patient or his legal representative must provide written informed consent prior to any research special examination or procedure.
  • 8\. International prognostic Index (IPI) >1 score.

Exclusion criteria

  • 1\. Have previously received systemic or local treatment including chemotherapy;
  • 2\. Previously received autologous stem cell transplantation;
  • 3\. Previous history of other malignant tumors, except skin basal cell carcinoma and cervical carcinoma in situ;
  • 4\. Accompanied by uncontrolled cardiovascular and cerebrovascular diseases, coagulation disorders, connective tissue diseases, serious infectious diseases and other diseases;
  • 5\. Primary central nervous system lymphoma;
  • 6\. Left ventricular ejection fraction ≤ 50%;
  • 7\. Laboratory test values at the time of screening (unless due to lymphoma); A. Neutrophils <1.5\*109/L; B. Platelet <75\*109/L; C. ALT or AST were 2 times higher than the upper limit of normal, AKP and bilirubin were 1.5 times higher than the upper limit of normal.

D. Creatinine levels higher than 1.5 times the upper limit of normal

  • 8\. Other concurrent and uncontrolled medical conditions that the investigator believes will affect patient participation in the study.
  • 9\. Patients with mental illness or other patients known or suspected to be unable to fully comply with the study protocol;
  • 10\. Pregnant or lactating women;
  • 11\. People living with HIV.
  • 12\. Patients with positive HbsAg test results need to undergo HBV DNA test, and can be enrolled before turning negative. In addition, if the HBsAg test result is negative, but the HBcAb test is positive (regardless of the HBsAb status), HBV DNA test should also be performed. If the result is positive, the treatment should also be negative before admission.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

China · 1 center
  • No. 197 Ruijin 2nd Road, Huangpu District, Shanghai — Shanghai

Identifiers

NCT: NCT06750991 · CSIIT-B45

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗